Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow amprelo

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus E

August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biot

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cas

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

The Merger Agreement contains certain customary termination rights for the Company and Parent. Subje

Drugmaker ​Zymeworks ‌said ​on ​Monday ⁠it ​will ​buy ​Theravance ​Biopharma in ‌a $929 ⁠million ​de

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarini

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “C

Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cry

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients rega

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biote

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biote

Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier mil

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus E

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Applicatio

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare a

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HE

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting p

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe

Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for i

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings a

Upgrades

  On Wednesday, 297 companies achieved new lows for the year.